Active Biotech’s new share issue oversubscribed

2018-04-16

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR CANADA OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.

 

Active Biotech AB’s (publ) (“Active Biotech”) new issue with preferential rights for Active Biotech’s shareholders have övertecknats. Active Biotech is supplied thereby to a rights offering proceeds of approximately sek 48 million before issue expenses.

After the completion of the subscription period shows the count of Active Biotech’s rights issue to 46 661 187 shares, corresponding to approximately 96 per cent of the offered shares, were subscribed for with subscription rights. In addition, the notifications for subscription without preferential rights, equivalent to 14 649 060 shares received, which corresponds to about 30 per cent of the rights issue. The issue guarantee has therefore not been utilized.

The allocation of the new shares subscribed for without subscription rights has been in accordance with what is specified in the prospectus. The people who have been allocated shares without support of subscription rights will be communicated separately. Nominee-registered shareholders will receive notice of award in accordance with instructions from the respective nominee. Only those who receive the award will be announced.

Through the rights issue are added to Active Biotech with approximately sek 48 million before issue expenses. Through the share issue, Active Biotech’s share capital, with about 250,000 to about 750,000, and the number of shares and votes increases by 48 412 160 to 145 236 480.

The new shares are expected to be admitted to trading on Nasdaq Stockholm in the end of april 2018.

For further information, please contact:

Hans Kolam, CFO

Tel: 046 19 20 44

E-mail: hans.kolam@activebiotech.com

Active Biotech AB

Box 724, 220 07 Lund, Sweden

Tel 046-19 20 00

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company focused on the development of drugs for the treatment of neurodegenerative/inflammatory diseases and cancer. Laquinimod, a substance in tablet form with unique immunomodulatory properties is in development for neurodegenerative diseases in collaboration with Teva Pharmaceutical Industries Ltd. ANYARA, a form of immunotherapy, is in development for the treatment of cancer in cooperation with the NeoTX Therapeutics Ltd. Furthermore, the conducted commercial activities for the projects tasquinimod, paquinimod and SILC. For further information please visit www.activebiotech.com.

IMPORTANT INFORMATION

This press release is not an offer to subscribe for shares in Active Biotech investors should not subscribe for or acquire any securities other than on the basis of information contained in the prospectus.

This press release may not be published or distributed, directly or indirectly, in or into the united states, Australia, Japan or Canada or in any other jurisdiction where distribution of this press release would be illegal. This press release does not constitute either an offer to sell new shares, BTA or subscription rights of any person in any jurisdiction where it would not be permitted to submit such an offer to such person or where such action would require additional prospectuses, registration or measures other than those pursuant to Swedish law. The prospectus, application form and other to the rights issue related documents may not be distributed in or into any country where such distribution or the rights issue would require measures as stated in the preceding sentence or where they would conflict with regulations in such country.

The new shares, BTA and subscription rights have not been recommended or approved by any u.s. federal or state securities regulatory authority or regulator. No new shares, subscription rights or other securities issued by Active Biotech have been or will be registered under the applicable United States Securities Act of 1933, or under the securities laws of any state of the united states. Therefore, no new shares, subscription rights or other securities issued by the Company to be transferred, used, or offered for sale in the united states, other than in such exceptional cases that do not require registration or in a transaction not covered by such a registration. There is no intention to register any portion of the rights issue in the united states and the securities issued in the rights issue will not be offered to the public in the united states.

The company has not authorized any offer to the public in respect of the securities referred to in this press release in any other country within the European economic area (“EEA”) other than Sweden. In other member states of the EEA, therefore, can the securities be offered only to (i) a qualified investor as defined in the directive of the european Parliament and of the council direct 2003/71/EC (the”Prospectus directive”) or (ii) any one falling under article 3(2) of the Prospectus directive.

This press release may in the Uk only distributed and directed only to “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) professional investors covered by article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (The”Order”), or (ii) persons falling within article 49(2)(a) to (d) (“high net worth”, etc) of Orders (collectively, “relevant persons”). In the Uk, such investment or other investment activities as referred to in this press release is only available to, and is directed only at, relevant persons. Any person who is not a relevant person should not act upon or rely on this communication or any of its content.

This press release may contain certain forward-looking information that reflects the Active Biotech’s current views with respect to future events and financial and operational development. Words such as “intends”, “will”, “anticipates”, “expects”, “may”, “plan”, “estimate” and other expressions which imply indications or predictions regarding future development or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking information does not constitute any guarantee of future results or development and actual results may materially differ from what is pronounced in the forward-looking information. This information, opinions and forward-looking statements contained in this press release apply only at this date and are subject to change without notice.

180416_Active Biotech’s new share issue oversubscribed

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Globenewswire

Leave a Reply